University of Chicago: Leukemia, Myeloid, Acute trials

The registry lists 12 Leukemia, Myeloid, Acute studies with University of Chicago as lead sponsor. 0 are open to participants now and 5 have results posted.

Early Phase 1 1Phase 1 6Phase 2 4No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell TransplantationCompletedNCT02981914Early Phase 1Results posted
• The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS PatientsTerminatedNCT02648932Phase 2Results posted
• Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01839916Phase 2Results posted
• High-dose Cytarabine/Mitoxantrone Followed by Autotransplantation for t-MDS/t-AMLCompletedNCT00774046Phase 2Results posted
• T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic MalignanciesCompletedNCT00683046Phase 2Results posted
• Studying Malnutrition And Sarcopenia In Older Adults With Acute Myeloid LeukemiaCompletedNCT05458258
• Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid LeukemiaActive, not recruitingNCT03844815Phase 1
• Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid LeukemiaCompletedNCT02573363Phase 1
• Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After TransplantCompletedNCT02485535Phase 1
• Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell TransplantSuspendedNCT02333162Phase 1
• Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete RemissionCompletedNCT01842139Phase 1
• Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid LeukemiaCompletedNCT01839240Phase 1